Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a leading pharmaceutical company in China, has entered into an exclusive agency agreement with South Korea’s Cellontech Co., Ltd., securing sole agency rights for the distribution of Cellontech’s CartiZol in mainland China. Financial details of the agreement have not been disclosed.
CartiZol, a pioneering product in South Korea, is an intra-articular injection that utilizes collagen to provide a protective coating on the cartilage membrane and surrounding tissues, thereby enhancing joint strength and lubrication. The product is designed to reduce friction and improve the viscoelastic properties of human cartilage. Additionally, it serves to supplement and coat damaged joint cartilage tissue, aiding in the natural healing process. CartiZol has demonstrated efficacy in alleviating symptoms of joint swelling and pain, aiding in the repair of damaged joints, and exerting anti-inflammatory effects.- Flcube.com
